Experimental Research On Sustained-released Intraperitoneal Chemotherapy With 5-fluorouracil

To evaluate the preponderance of intraperitoneal sustained-realesed chemotherapy with 5-FU we investigated the concentration of 5-FU in the rabbit portal vein by HPLC and evaluated the inhibitory effect on the growth of H22 ascitic tumor and the sensitivity of H22 cells to 5-FU in the mouse models. The results suggest that intraperitoneal sustained-released chemotherapy can lengthen the time of effective concentration of 5-FU in the portal vein and enlarge the AUC in the concentration-time curve. After the models of H22 ascitic tumor in mice were established, sustained-released 5-fluorouracil and 5-FU were administered by intraperitoneal injection. Intraperitoneal sustained-released chemotherapy with 5-FU can lengthen the life spans of mice bearing H22 ascitic tumor cells and increase the apoptosis ratio of H22 cells in a longer period of time relatively. By En Vision immunocytochemical method, the expression of TP and DPD protein was evaluated, and by fluorescence quantitative Polymerase chain reaction, the expression of TPmRNA and DPDmRNA in H22 ascitic cells was determined at the level of mRNA. Regarding the sensitivity of H22 cells to 5-FU, intraperitoneal sustained-realesed chemotherapy has preponderance than intraperitoneal chemotherapy.